Ben Jealous is serious about legalizing marijuana in Maryland if he wins the state’s gubernatorial election in November. And with early polls showing him in the lead as the June 26 Democratic primary approaches, the former NAACP president might just get his shot.
For Jealous, a progressive candidate endorsed by Sens. Bernie Sanders (I-VT) and Kamala Harris (D-CA), among others, his stance on cannabis policy has evolved over time—but he’s put full legalization front and center during his gubernatorial campaign.
Marijuana Moment reached Jealous by phone to learn more about his plans for marijuana reform if elected governor.
This interview has been lightly edited for length and clarity.
Marijuana Moment: You tweeted recently that comedian Dave Chappelle was the first person to tell you that cannabis should be legal. Can you describe that conversation and how it influenced your own personal views?
Ben Jealous: We were young and we were 20 years old in Mississippi. And Dave had come down there. I was organizing to stop a governor from turning a black college into a prison, and I was stressed out because Dave wanted to fire up a joint, and I didn’t want to go to jail in Mississippi. Dave was like ‘well, this shit should be legal,’ and I was like, ‘yeah, but it’s not.’ That was basically the conversation.
When I was 20 I was known as “Dave Chappelle’s bodyguard”.
Now that I’m 45, I’m proud to be: “Dave Chappelle’s Candidate.”
And, if you’re wondering, yes he was the first person to tell me Cannabis should be legal for adults.
I was skeptical then.
I agree with him now. https://t.co/ovQKVlhmcx
— Ben Jealous for Governor (MD) (@BenJealous) June 5, 2018
And then it was just an ongoing conversation about the history of marijuana enforcement—the way it was targeted at our community and Latino communities, and that just sort of opened my eyes. And that led me as president of the NAACP pushing for decriminalization in a number of states and cities. That’s ultimately where that conversation led. Dave was the one who really first talked to me about the way in which marijuana enforcement had been targeted at our communities. It just so happened that that day in Mississippi, the stakes were so high, I wasn’t really having it.
MM: Let’s talk more about the evolution of your position on cannabis reform. Were there any other major factors that led you to adopt a pro-legalization stance?
BJ: I did not start the campaign thinking that this was going to be one of the big issues that I was going to be talking about. However, I did start the campaign knowing that we were going to have to deal head on with the violence in Baltimore and the shootings elsewhere around the state, including places like Prince George’s County. And so around the second anniversary of the uprisings in Baltimore, I asked a retired member of the Baltimore Police Department to go talk to commanders that he knew across the city and just ask them, ‘why are the shootings surging? What’s going on with the violence?’
We can either tax and regulate cannabis for adult use, reduce violence, and enrich our state.
We can continue a policy that enriches the cartels & has always had a racially biased pattern of enforcement.
Some politicians see this as a real dilemma.
I don’t. #LegalizeIt
— Ben Jealous for Governor (MD) (@BenJealous) February 7, 2018
And he came back and he said, ‘Ben, you know, there were two big data points.’ I said, ‘OK, what are they?’ He said, ‘one, nobody can really agree why the shootings have been surging in recent years. However, everybody is in agreement that approximately half of the shootings in the past 10 years had been one set of marijuana dealers killing another set of marijuana dealers.’ That made me sit up straight, because it really laid bare that we could be saving lives if we legalized cannabis. And that added to the mountains of evidence of the good that could be done to advance racial justice, the good that could be done to increase revenues for universal pre-k.
MM: It’s estimated that full legalization would bring in upwards of $120 million in tax revenue for Maryland. What’s your top priority in terms of how you’d like to see that revenue allocated?
BJ: One of the things that excites me, as I look forward to the day when we legalize cannabis in Maryland, is that we know that when we do, we will be able to decrease the shootings in Baltimore and throughout the state, and we’ll be able to increase five-year-olds’ readiness to start kindergarten. It’s a great win-win. And it’s rare in politics, but it’s also urgently needed. We know that we have to end mass incarceration—and yet go further. We have to really get back to opening up the gates of opportunity for all of our children. And by legalizing cannabis, we get to make progress on both fronts.
My education plan calls for taxing and regulating marijuana for adult use and using those funds to pay for universal pre-k.https://t.co/HibjLgIwyD
— Ben Jealous for Governor (MD) (@BenJealous) May 18, 2018
We’ll be able to decrease the number of people going into prisons, we’ll be able to make our streets safer and cut the violence on our streets significantly, but we’ll also be able to generate tax revenues that will cover the costs of providing universal pre-k for every child in the state. And that itself will strike a blow against mass incarceration because we know that the better prepared a child is for kindergarten, the more likely they are to do well in school and stay in school and end up in a good job. It’s a true win-win.
MM: What would your message to Democratic presidential candidates in 2020 be when it comes to the issue of legalization?
BJ: Speaking as a Democrat, as party that is committed to being the party of working people, the party of economic justice, the party of racial justice, the party of civil rights, it should be an easy decision at this point. States like Colorado and Washington, D.C and Washington State have led the way, shown that it decreases violence, and it increases tax revenues, while taking the money out of the pockets of gangs and cartels that are engaged in a lot of other very dangerous criminal activities. It’s just common sense—and courage and common sense should be the hallmarks of the Democratic party.
MM: Can you speak to the importance of strengthening the state’s diversity requirements for marijuana licenses?
BJ: Let us never forget that this is the 21st century. Our Republican governor rolled out the new medical cannabis as if it were the 19th century. In a state that’s 53 percent women and 48.5 percent people of color, 100 percent of the licenses went to white-owned companies and virtually none went to women. That should never be allowed to happen again. When I’m governor, we will go further. We will make sure that the ownership is inclusive, but we’ll also make sure that people from the neighborhoods that have been adversely affected by the war on drugs are included in both ownership and employment. The illegal cannabis trade has been a steady employer in a lot of very poor neighborhoods like Upton, where my mom grew up in West Baltimore. We must build this industry in a way that lifts up the people from the places that have paid the steepest price in the war on drugs.
Photo courtesy of Gage Skidmore.
Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer
“These aren’t just numbers and there are families attached.”
By Ned Oliver, Virginia Mercury
Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.
The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.
Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.
The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.
Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.
The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.
“As of right now, the process is proceeding,” he said.
The Virginia Joint Commission on Cannabis Oversight is meeting now. You can find the agenda and links to livestream and to provide public comment at https://t.co/f1wsPn7SV7
— Jennifer McClellan (@JennMcClellanVA) October 14, 2021
Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.
Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.
They said it remains unknown how many more are being held because of marijuana related probation violations.
“These aren’t just numbers and there are families attached,” Burger said.
DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.
In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.
DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.
It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.
LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.
Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.
Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:
For all other THC, psilocybin, psilocyn and MDMA:
And for other psychedelic substances like LSD, mescaline and DMT:
DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.
“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.
“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”
Here are the exact numbers for the proposed 2021 and 2022 quotas:
|All other tetrahydrocannabinol||1,000||2,000|
A 30-day public comment period will be open after the notice is formally published on Monday.
It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.
National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.
Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.
A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.
Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.
Image element courtesy of Kristie Gianopulos.
Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred
The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.
The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.
Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.
Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.
But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.
Disappointed but not surprised U.S. Supreme Court declined to hear our case. We’re pursuing our claims in federal court. As that litigation proceeds, Biden administration will have to take a position, which it avoided by waiving its right to respond to our Supreme Court petition.
— Safehouse (@SafehousePhilly) October 13, 2021
“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”
That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.
“If they don’t respond, they lose,” Goldfein said.
A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.
Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.
If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.
The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.
Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.
A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.